VFA
KPTI icon

Virtus Fund Advisers’s Karyopharm Therapeutics KPTI Stock Holding History

Virtus Fund Advisers’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$355K Buy
+2,465
New +$396K ﹤0.01% 394
2014
Q3 		– Sell
-70
Closed -$49K – 1548
2014
Q2 		$49K Buy
+70
New +$32.6K ﹤0.01% 1881

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Virtus Fund Advisers's KPTI Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Karyopharm Therapeutics (KPTI) in Q4 2017: 2,465 shares worth $355K. The stake represents ﹤0.01% of the portfolio and ranks #394 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in KPTI as recently as Q2 2014.

Virtus Fund Advisers first reported a position in KPTI in Q2 2014 and has held it in 2 quarters since. 90 funds tracked by Wall St. Rank hold KPTI as of Q4 2017.

  • Virtus Fund Advisers held 2,465 shares of Karyopharm Therapeutics worth $355K as of Q4 2017.
  • Karyopharm Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Karyopharm Therapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #394 holding.
  • Virtus Fund Advisers first reported a position in Karyopharm Therapeutics in Q2 2014 and has held it in 2 quarters since.
  • 90 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.